The ESCCA Conferences have become of major importance for education and scientific exchange in the fields of basic, translational and clinical applications in cytometry, in particular, flow cytometry applications and in Hematology, Immunology, Cancer and Cell Biology.
Due to the COVID-19 pandemic, ESCCA 2021 will be a VIRTUAL Conference.
Accreditation by the European Accreditation Council for Continuing Medical Education (EACCME) will be applied for.
The virtual programme includes live plenary sessions, pre-recorded parallel educational sessions with live Q&A in the fields of Hematology-Oncology, Data analysis and Immunology, and Best Abstract Presentation sessions. Posters will be available as pre-recorded PowerPoint presentations and e-posters.
All lectures and e-poster presentations will remain on-demand up to 6 months after the Conference.
The preliminary full programme and the programme at a glance can be downloaded here:
The Scientific Committee welcomes the submission of your abstract for original research papers for presentation. Do submit your abstract to actively participate in the Conference! Abstract submission is now open.
Antigen-specific immunity: In the wake of huge immunotherapeutic successes in many areas of medicine, particularly cancer, ESCCA has developed a new, dedicated guest track that will reflect the latest developments in this new exciting area with a particular focus on the application and monitoring of immunotherapies. The new parallel programme track will be closely coordinated with all relevant immunological and clinical topics.
Data analysis: from general principles of flow data representation/analysis to data handling and repositories, from data preparation to high-dimensional data analysis and large cohort – aspects we need to know about modern data analysis.
The virtual conference forrmat requires a more condensed programme. Sadly, the pre-conference courses will not be offered during the virtual conference in April. However, (some of) these courses may be organised as a webinar later in 2021.